Are You Sure Your Lab Is Clean?

| February 13, 2017 | Sponsored

article image
Cleanrooms and other classified areas in healthcare and pharmaceutical facilities must be kept in a state of microbial control in order to maintain aseptic conditions and ultimately protect the product or patient. The current GMP lays the foundation for ensuring adequate conditions in a general sense. Cleanliness of a manufacturing operation includes control of air quality as well as surface cleaning and disinfection in manufacturing areas. These conditions, combined with careful and thorough evaluation of the chemical agents used for the cleaning and disinfection program, should help achieve the specified cleanliness standards and control of microbial contamination of products.

Spotlight

Dyax

Shire acquired Dyax on January 21, 2016. Following this date, this page will no longer be actively monitored. There will be no updates or responses posted on this page. Please visit Shire's LinkedIn page at https://www.linkedin.com/company/shire or www.shire.com for more information.

OTHER ARTICLES

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Selexis Cell Line Development Strategies

Article | February 18, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 18, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

Dyax

Shire acquired Dyax on January 21, 2016. Following this date, this page will no longer be actively monitored. There will be no updates or responses posted on this page. Please visit Shire's LinkedIn page at https://www.linkedin.com/company/shire or www.shire.com for more information.

Events